Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,166.9
-13.7 (-0.43%)

 

  • STI Straits Times Index
    3,166.9
    -13.7 (-0.43%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,494.6
    -18.3 (-1.21%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,961.0
    -354.3 (-1.35%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,397.4
    -14.4 (-0.42%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,283.6
    -498.8 (-1.80%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,070.0
    -50.7 (-0.83%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,329.7M
  • Value: 1,564.3M
  • Rise: 137
  • Fall: 185
  • Unch: 438

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.115+0.007
Hong Lai Huat0.107+0.003
RH PetroGas0.175-0.007
Singtel2.270-0.010
Shen Yao0.006-0.001
Golden Agri-Res0.230-0.005
CapLand IntCom T2.150+0.010
Genting Sing0.810-0.010
Mercurius0.061-
GKE0.146-0.007

World Indices

World Indices
Name Last Change
Nasdaq 14,672.7 -105.6
HSI 25,961.0
HSCEI 9,233.2
Jakarta 6,070.0
Nikkei 225 27,283.6
SSE Comp 3,397.4
Shanghai A 3,560.7
Shanghai B 254.0
KOSPI 3,202.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Merck Tbk. MERCK INDONESIA
Quotes 10 Minutes Delayed. Updated at 30 Jul 2021 15:10
Last (IDR): 3,320.000 Change: -30.000 High: 3,350.000 Remarks: -
Change (%): -0.90 Low: 3,300.000
Open 3,350.000 Yesterday's Close 3350.000
Buy Price 3310.000 Sell Price 3320.000
Buy Volume ('000) 2.9 Sell Volume ('000) 9.3
Cumulative Volume ('000) 29.5 Cumulative Value 98,345,000
Click to show Stock Prices chart

Key Statistics

EPS (IDR) a 160.49612 Trailing EPS (IDR) e 201.39939 NAV (IDR) b 1,486.6030
PE a 20.686 Trailing PE f 16.485 Price / NAV b 2.2333
Dividend (IDR) d 122.000000 Cash In Hand (IDR) g 367.6423 Issued & Paid-up Shares c 448,000,000
Dividend Yield (%) d 3.675 Price / Cash In Hand g 9.031 Treasury Shares h -
Beta - 75 Daysi 0.042 R-Squared - 75 Days(%)i 0.05 Market Cap (M) 1,487,360.000
Beta - 500 Daysi 0.925 R-Squared - 500 Days (%)i 24.39 Enterprise Value (M) 1,346,750.362
Piotroski F Score 8 Exchange Code MERK Par Value ( IDR ) 50.00000
52 Weeks Volatility (%) 26.24 6-Month VWAP 3289.200 Free Float (%) 13.3
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 22 Dec 2015.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 29 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Merck Tbk. IDX 1,487,360.000 20.686 16.485 2.2333 3.675
Industry Pharmaceuticals: Major IDX 5,890,016.651 75.967 69.176 2.1921 1.616
Local Peer Kimia Farma Tbk. IDX 14,773,640.003 837.563 1,684.562 2.1047 0.048
Local Peer Soho Global Health Tbk. IDX 6,320,466.600 36.724 36.724 2.7064 4.739
Local Peer Phapros Tbk. IDX 978,600.000 20.182 14.085 1.3464 1.982
Global Peer JOHNSON & JOHNSON NYSE 453,313.056 30.808 25.514 6.5150 2.311
Global Peer PFIZER INC NYSE 239,637.109 24.921 18.116 - 3.554
Global Peer ELI LILLY AND COMPANY NYSE 233,522.831 37.703 38.330 33.8505 1.213
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 224,916.064 27.698 25.007 4.1619 2.086
Global Peer ABBVIE INC NYSE 205,411.386 45.086 40.403 14.9827 4.159
Global Peer MERCK & CO INC NYSE 194,639.452 27.542 48.346 - 3.224
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 177,342.685 55.061 54.624 - 2.028
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 164,139.056 25.472 24.416 17.7561 1.453
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,814.606 - - 4.0973 2.738
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,276.652 9.281 36.392 - 2.594
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), REPLIGEN CORP (NASDAQ), CUREVAC NV (NASDAQ), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), SINOPHARM (HKEx), HUTCHMED (HKEx), ORGANON & CO (NYSE), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REMEGEN-B (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), HYGEIA HEALTH (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TRAD CHI MED (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), CHINAGRANDPHARM (HKEx), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), EVEREST MED-B (HKEx), HENLIUS (HKEx), IGM BIOSCIENCES INC (NASDAQ), CSTONE PHARMA-B (HKEx), CARSGEN-B (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), SSY GROUP (HKEx), QUANTERIX CORPORATION (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HEPALINK (HKEx), OCUMENSION-B (HKEx), ADC THERAPEUTICS SA (NYSE), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), ZYMEWORKS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), UNITED LAB (HKEx), REPARE THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ANTENGENE-B (HKEx), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), IMMUNOTECH-B (HKEx), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PETIQ INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CKLIFE SCIENCES (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), SCICLONE PHARMA (HKEx), GH RESEARCH PLC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ANNEXON INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), SHINEWAY PHARM (HKEx), AKERO THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), EVOLUS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), PHARVARIS NV (NASDAQ), ZHAOKE OPHTH-B (HKEx), VERU INC (NASDAQ), AC IMMUNE SA (NASDAQ), CLENE INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), IGBB (Bursa), ATHENEX INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), BIOMEA FUSION INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), RACE ONCOLOGY LTD (ASX), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), AFT PHARMACEUTICALS LTD (ASX), GRITSTONE BIO INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), DURECT CORP (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), 89BIO INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), TOT BIOPHARM-B (HKEx), GAMIDA CELL LTD (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), CLEARSIDE BIOMEDICAL INC (NASDAQ), ANNOVIS BIO INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), SOL GEL TECHNOLOGIES LTD (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), OVID THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), FUSEN PHARM (HKEx), NEXIMMUNE INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), VINCERX PHARMA INC (NASDAQ), IMMUNIC INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), OBSEVA SA (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), IP (SET), TRICIDA INC (NASDAQ), CH BIOTECH SER (HKEx), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), ZHONGZHIPHARM (HKEx), GENPREX INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), IX Biopharma (SGX), ETON PHARMACEUTICALS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), ENTERA BIO LTD (NASDAQ), NOVAN INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), EYENOVIA INC (NASDAQ), PROPHASE LABS INC (NASDAQ), GALECTO INC (NASDAQ), MEDIWOUND LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), NEW RAY MEDIC (HKEx), CHARMACY PHAR (HKEx), APREA THERAPEUTICS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GRAYBUG VISION INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), PAK FAH YEOW (HKEx), ALLENA PHARMACEUTICALS INC (NASDAQ), Hyphens Pharma (SGX), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), NOVA (Bursa), INVION LTD (ASX), MODERN CHI MED (HKEx), BIOHLDG (Bursa), BRICKELL BIOTECH INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), EXOPHARM LTD (ASX), ASSERTIO HOLDINGS INC (NASDAQ), MANNATECH INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), NEP INTERLONG (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), VIRIOS THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), WAI YUEN TONG (HKEx), SYNAPTOGENIX INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), ACER THERAPEUTICS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), EXTRAWELL PHAR (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), PHARMAXIS (ASX), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), SUNZEN (Bursa), NLS PHARMACEUTICS LTD (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PAINREFORM LTD (NASDAQ), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IMMURON LIMITED (ASX), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --10.000
-0.30 %
10 Days -+80.000
+2.47 %
20 Days -+120.000
+3.75 %
Medium Term Return 3 Months 122.000+50.000
+5.26 %
6 Months 122.000+380.000
+17.07 %
1 Year 20532.000-340.000
+551.69 %
Long Term Return 2 Years 20532.000-460.000
+531.01 %
3 Years 23097.000-2830.000
+329.54 %
5 Years 23632.000-6580.000
+172.24 %
Annualised Return Annualised --
+22.18 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 2,600.000 - 3,790.000 Change From 1 Year Low +720.000 % Change From 1 Year Low (%) +27.69
Change From 1 Year High -470.000 % Change From 1 Year High (%) -12.40
2 Years Range 1,170.000 - 4,450.000 Change From 2 Years Low +2150.000 % Change From 2 Years Low (%) +183.76
Change From 2 Years High -1130.000 % Change From 2 Years High (%) -25.39
5 Years Range 1,170.000 - 10,050.000 Change From 5 Years Low +2150.000 % Change From 5 Years Low (%) +183.76
Change From 5 Years High -6730.000 % Change From 5 Years High (%) -66.97
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

PT Merck Tbk engages in the pharmaceutical and chemical businesses. It operates through the following segments: Biopharma, Consumer Health, and Others. The Biopharma segment offers ethical products. The Consumer Health segment focuses on over-the-counter products. The company was founded on October 14, 1970 and is headquartered in Jakarta, Indonesia.

Historical Price Data

Date Open High Low Close Volume VWAP
30 Jul 2021 3350.000 3350.000 3300.000 3320.000 29,500 3333.7288
29 Jul 2021 3360.000 3370.000 3330.000 3350.000 44,200 3341.2670
28 Jul 2021 3380.000 3380.000 3350.000 3370.000 17,400 3364.4253
27 Jul 2021 3410.000 3410.000 3340.000 3380.000 127,600 3365.6113
26 Jul 2021 3330.000 3400.000 3330.000 3390.000 103,600 3386.0039
23 Jul 2021 3360.000 3400.000 3330.000 3330.000 118,000 3366.7458
22 Jul 2021 3340.000 3370.000 3320.000 3360.000 16,000 3354.0625
21 Jul 2021 3420.000 3490.000 3300.000 3320.000 149,700 3341.4696
19 Jul 2021 3240.000 3500.000 3240.000 3400.000 224,700 3409.6351
16 Jul 2021 3250.000 3290.000 3220.000 3240.000 9,500 3246.9474
15 Jul 2021 3280.000 3320.000 3230.000 3250.000 117,400 3297.0102
14 Jul 2021 3230.000 3280.000 3210.000 3280.000 48,600 3259.4239
13 Jul 2021 3220.000 3230.000 3210.000 3220.000 32,700 3220.1529
12 Jul 2021 3200.000 3230.000 3180.000 3230.000 47,800 3216.9038
09 Jul 2021 3170.000 3170.000 3100.000 3170.000 34,900 3122.8653
08 Jul 2021 3170.000 3200.000 3150.000 3170.000 41,500 3172.7952
07 Jul 2021 3100.000 3180.000 3100.000 3160.000 25,400 3155.8268
06 Jul 2021 3200.000 3220.000 3100.000 3100.000 906,600 3116.7428
05 Jul 2021 3200.000 3220.000 3190.000 3190.000 47,000 3199.3404
02 Jul 2021 3200.000 3210.000 3190.000 3200.000 253,900 3199.7794
01 Jul 2021 3230.000 3300.000 3190.000 3220.000 360,200 3213.5619
30 Jun 2021 3270.000 3300.000 3230.000 3300.000 231,900 3297.6800
Summary
Current 2 Weeks
(16 Jul 2021 to 30 Jul 2021)
3250.000 3500.000 3220.000 3320.000 840,200 -
Previous 2 Weeks
(02 Jul 2021 to 15 Jul 2021)
3200.000 3500.000 3190.000 3250.000 1,555,800 -
4 Weeks from
(04 Jun 2021 to 01 Jul 2021)
3380.000 3500.000 3220.000 3220.000 2,468,400 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.